0001558370-24-005089.txt : 20240515 0001558370-24-005089.hdr.sgml : 20240515 20240415121933 ACCESSION NUMBER: 0001558370-24-005089 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm

​

Soligenix, Inc.

29 Emmons Drive, Suite B-10

Princeton, NJ 08540

​

April 15, 2024

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

Re:    

Soligenix, Inc.

Registration Statement on Form S-1

File No. 333-276511

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Soligenix, Inc. (the “Company”), the undersigned hereby requests that the Company’s Registration Statement on Form S-1 (File No. 333-276511), as amended, be declared effective on April 15, 2024, at 4:30 p.m., Eastern Daylight Time, or as soon as practicable thereafter.

​

The Company hereby authorizes its counsel, Driscoll R. Ugarte of Duane Morris LLP, to orally modify or withdraw this request for acceleration. Please contact Mr. Ugarte at (561) 962-2139 with any questions you may have concerning this request, and please notify him when this request for acceleration has been granted.

​

 

 

Very truly yours,  

 

SOLIGENIX, INC.

 

 

 

 

By:

 /s/ Christopher J. Schaber

 

 

Christopher J. Schaber, PhD

President and Chief Executive Officer

 

 cc:  Driscoll R. Ugarte, P.A.

Duane Morris LLP

​

​